The CASP9 Knockout K-562 Polyclonal Cells provide a CRISPR/Cas9-mediated polyclonal knockout model in the K-562 cell line, targeting the initiator caspase CASP9. This product consists of a heterogeneous population of edited cells, enabling loss-of-function studies of the intrinsic apoptotic pathway without clonal selection bias. The CRISPR/Cas9-edited polyclonal knockout cell population serves as a robust tool for investigating CASP9-dependent signaling and apoptosis regulation.
K-562 is a human lymphoblastoid cell line derived from a female patient with chronic myeloid leukemia in blast crisis. It serves as a widely used model for CML and hematopoietic lineage commitment, exhibiting BCR-ABL1-driven proliferation and apoptosis resistance. This background is particularly relevant for studying leukemic cell signaling, drug resistance, and the role of apoptosis in hematopoietic malignancies.
CASP9 is the initiator caspase activated downstream of mitochondrial cytochrome c (CYCS) release. Upon apoptotic stimuli, CYCS binds APAF1, promoting apoptosome assembly and procaspase-9 recruitment, leading to CASP9 autocatalytic activation. Active CASP9 then cleaves and activates executioner caspases CASP3 and CASP7. Regulatory interactions include inhibition by XIAP and modulation by HSPs. Upstream, BCL-2 family proteins like BCL-2 and BAX control mitochondrial permeability, while TP53 transcriptionally regulates pathway components. Thus, CASP9 integrates diverse stress signals to execute apoptosis.
In K-562 cells, CASP9 knockout permits dissection of intrinsic apoptosis in the context of BCR-ABL1-mediated survival signaling. This model is valuable for probing mechanisms of resistance to tyrosine kinase inhibitors and conventional chemotherapies, as K-562 cells often display apoptotic dysregulation. It also facilitates studies of crosstalk between apoptosis and differentiation, and validation of CASP9 as a target in leukemia and solid tumors. The knockout cells enable mapping of apoptotic signaling networks in a disease-relevant setting.
Typical applications include caspase activity assays, western blotting for CASP9, CASP3, and CASP7, and apoptosis induction with staurosporine followed by flow cytometric Annexin V staining. The model supports chemosensitivity profiling, cytochrome c release assays, and RT-qPCR analysis. These cells are suited for screening pro-apoptotic compounds and studying drug resistance mechanisms. For detailed technical support or custom requests, please contact Ascent Research.
